Patent · US Active

Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones

US9827226B2 · kind B2 · utility

0Cited by

2References

11Claims

0Family size

Assignee

BeiGene, Ltd. · KY

Inventors

Bo Ren · Beijing, CN
Changyou Zhou · Princeton, US
Hexiang Wang · Beijing, CN

Key dates

Filing date	Jun 6, 2016
Grant date	Nov 28, 2017
Priority date	—
Expiry date	Jun 6, 2036

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-one compounds, pharmaceutical compositions comprising at least one such 4 substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-one compound processes for the preparation thereof, and the use thereof for inhibiting BET family of bromodomains and for treating disorders mediated thereby, such as certain cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.